化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
目的探讨白三烯（LT）B4能否不依赖细胞核因子资B受体激活剂配体（RANKL）直接促进人破骨细胞的分化和激活。
Objective To determine whether leukotriene B4 (LTB4) could directly stimulate human osteoclast differentiation and activation independent of RANKL (ODF).
这些核激素受体由其配体(激活物)激活后，通过偶联特异的反应元件来调控多种靶基因的表达。
After activation by ligand as is the case with nuclear receptors, PPARs binds to a specific element in the promoter region of target genes.
人们很早就知道，EGFR配体使受体二聚化，这种二聚化导致激酶结构域的激活；
It had long been known that the EGFR ligand dimerizes the receptor and that this dimerization converts into an activation of the kinase domain;
人们很早就知道，EGFR配体使受体二聚化，这种二聚化导致激酶结构域的激活；
It had long been known that the EGFR ligand dimerizes the receptor and that this dimerization converts into an activation of the kinase domain;
应用推荐